Saudi Arabia’s leading pharmaceuticals firm Tabuk Pharmaceuticals has signed an agreement with the US-based biotechnology company Moderna to commercialize the Moderna COVID-19 Vaccine and future variant-specific booster candidates in the Kingdom.
Under the terms of this agreement, Tabuk Pharmaceuticals will have the marketing authorization for the Moderna COVID-19 vaccine in Saudi Arabia. Further, Tabuk will be able to negotiate the potential to market other Moderna mRNA products if they are approved in the future, in addition to the Moderna COVID-19 vaccination and updated variant booster candidates.
Mr. Stéphane Bancel, Chief Executive Officer of Moderna said, “We appreciate the collaboration of Tabuk Pharmaceuticals in this new partnership in Saudi Arabia. It is thanks to partnerships such as these that we can expand access to our vaccine globally, and we hope it will support the availability of our COVID-19 vaccine for the benefit of the people of Saudi Arabia.”
Corinne Le Goff CCO – Moderna
“We welcome the opportunity to work with Tabuk Pharmaceuticals to bring the Moderna COVID-19 and potentially other Moderna mRNA products to Saudi Arabia in the future. Together with our partners, we remain committed to delivering our vaccine to more populations around the world. We are pleased to have secured a new agreement to supply our COVID-19 vaccine and our updated variant booster vaccine candidate, if authorized, to Saudi Arabia for 2021 and 2022.”
“We are proud and excited at Tabuk to be partnering with Moderna to commercialize crucial vaccines to Saudi Arabia building on our strategy to expand our specialty and innovative business and reinforces our leading position in the region. We aspire to be the partner of choice to Moderna in the region and consider further strategic collaboration including local manufacturing in Saudi,” commented Mr. Wisam Alkhatib, Vice President of Strategy and Business Development of Tabuk Pharmaceuticals.
